Iovance Biotherapeutics Stock Performance
| IOVA Stock | USD 3.44 -0.04 -1.15% |
Risk-Adjusted Performance
Contained
Weak | Strong |
Compared with the broader market, risk-adjusted returns on Iovance Biotherapeutics rank lower than 5% of all global equities and portfolios over the last 90 days. In practice, the ranking separates absolute gains from efficient gains. Despite somewhat weak basic indicators, Iovance Biotherapeutics sustained solid returns over the last few months and may actually be approaching a breakout point. Learn More
Actual Historical Performance (%)
One Day Return -1.15 | Five Day Return -8.27 | Year To Date Return 26.01 | Ten Year Return -41.20 | All Time Return -96.87 |
Last Split Factor 1:100 | Last Split Date 2013-09-26 |
1 | Disposition of 16450 shares by Kirby Daniel Gordon of Iovance Biotherapeutics at 2.6 subject to Rule 16 b-3 | 02/10/2026 |
2 | Iovance Biotherapeutics Projected to Post Earnings on Tuesday | 02/17/2026 |
3 | Disposition of 4464 shares by Igor Bilinsky of Iovance Biotherapeutics at 2.23 subject to Rule 16 b-3 | 02/20/2026 |
4 | Iovance Biotherapeutics Inc Q 4 2025 Earnings Call Highlights Strong Revenue Growth and ... | 02/24/2026 |
5 | A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts | 03/03/2026 |
6 | Iovance Biotherapeutics Is Up 42.7 percent After Positive Lifileucel Sarcoma Data And New Trial Plan | 03/10/2026 |
7 | Acquisition by Igor Bilinsky of 117500 shares of Iovance Biotherapeutics subject to Rule 16 b-3 | 03/11/2026 |
8 | Analyst Sentiment Remains Strong on Iovance Biotherapeutics Amid U.S. Rollout of Melanoma Drug, Amtagvi | 03/20/2026 |
9 | Is Iovance Biotherapeutics Offering A Compelling Opportunity After Recent Price Swings | 03/25/2026 |
10 | A Look At Iovance Biotherapeutics Valuation After Strong Amtagvi Data And Growing Pipeline Momentum | 04/09/2026 |
11 | Iovance Biotherapeutics Shares Down 6.6 percent Heres Why | 04/10/2026 |
12 | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 | 04/17/2026 |
13 | Chardan Maintains a Buy on Iovance Biotherapeutics | 04/20/2026 |
14 | Will FDAs RP 1 Setback Refocus Iovance Biotherapeutics Post-Checkpoint Melanoma Narrative | 04/22/2026 |
Performance Related Modules
Earnings links to analyst estimate history and revisions, Ownership shows shareholder mix, Profitability focuses on margin and return ratios, Liquidity covers cash-flow strength and short-term funding capacity, and Fundamentals groups the broader financial ratio set.
Relative Risk vs. Return Landscape
If you had invested $ 289.00 in Iovance Biotherapeutics on January 26, 2026 and sold it today you would have earned a total of $ 55.00 from holding Iovance Biotherapeutics or generated 19.03% return on investment over 90 days. Iovance Biotherapeutics is currently generating a 0.4634% daily expected return and carries 6.4263% risk (volatility on return distribution) over a 90-day horizon. In relative terms, Iovance exhibits above-average volatility, exceeding roughly 43% of comparable stocks, and IOVA has trailed 91% of traded instruments in return over the 90-day horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
Price convergence toward a historical mean is a well-documented pattern for stocks like Iovance Stock. Although this tendency is a useful forecasting input, some instruments remain persistently mispriced before market correction.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 3.44 | 90 days | 3.44 | about 50.0 |
Our distribution model estimates the likelihood of Iovance Biotherapeutics moving above the current price in 90 days from now at about 50.0 . Past return patterns over this horizon reflect a distribution that has favored above-current-price scenarios. (This Iovance Biotherapeutics distribution emphasizes the price range most consistent with recent behavior in Iovance Stock over a 90-day period).
Iovance Biotherapeutics Price Density |
| Price |
Predictive Modules for Iovance Biotherapeutics
Investors apply quantitative and fundamental models to forecast Iovance Biotherapeutics within the stock market. Combining results from different methods frames the confidence level warranted by Iovance Biotherapeutics predictions.Statistical evidence for mean reversion in Iovance Biotherapeutics' appears through its tendency to revert after extreme valuations. Under mean reversion theory, Iovance Biotherapeutics' price extremes are viewed as temporary dislocations that may self-correct.
Primary Risk Indicators
Significant market corrections and rallies over the last two decades have made the stock market challenging for Iovance Biotherapeutics investors. Dramatic market moves have periodically reshaped the risk landscape for holders of Iovance Biotherapeutics.α | Alpha over Dow Jones | 0.67 | |
β | Beta against Dow Jones | 2.24 | |
σ | Overall volatility | 0.70 | |
Ir | Information ratio | 0.10 |
Investor Alerts and Insights
Tracking Iovance Biotherapeutics through automated alerts focuses attention on the most impactful stock developments. Reviewing Iovance Biotherapeutics notifications is an efficient way to stay current on technical patterns and fundamental changes.| Iovance Biotherapeutics had very high historical volatility over the last 90 days | |
| IOVA reported previous year's revenue of 263.5 M. Net Loss for the year was -390.98 M with profit before overhead, payroll, taxes, and interest of 90.32 M. | |
| Iovance Biotherapeutics currently holds about 424.46 M in cash as of latest reporting with -302.41 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Iovance Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 1925 shares by Matthias Bodenstedt of Moon Lake Immunotherapeuti at 19.51 subject to Rule 16 b-3 |
Price Density Drivers
Several forces contribute to Iovance Biotherapeutics' price dynamics, including buyer and seller positioning dynamics and market conditions. Monitoring Iovance Biotherapeutics' price density drivers provides context for distinguishing fundamental from tactical price moves.
| Common Stock Shares Outstanding | 357.3 M | |
| Cash And Short Term Investments | 297 M |
Iovance Biotherapeutics Fundamentals Growth
Market participants price Iovance Stock based on their assessment of Iovance Biotherapeutics' financial trajectory. Revenue and earnings growth, profitability metrics, and debt levels form the core fundamentals driving Iovance Stock.
| Return On Equity | -0.56 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | -1.48 | ||||
| Operating Margin | -0.85 | ||||
| Current Valuation | 1.17 B | ||||
| Shares Outstanding | 411.96 M | ||||
| Price To Earnings | -3.51 X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 5.38 X | ||||
| Revenue | 263.5 M | ||||
| Gross Profit | 90.32 M | ||||
| EBITDA | -357.11 M | ||||
| Net Income | -390.98 M | ||||
| Cash And Equivalents | 424.46 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 48.44 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 1.70 X | ||||
| Cash Flow From Operations | -302.41 M | ||||
| Earnings Per Share | -1.09 X | ||||
| Market Capitalization | 1.42 B | ||||
| Total Asset | 913.17 M | ||||
| Retained Earnings | -2.78 B | ||||
| Working Capital | 304.33 M | ||||
| Current Asset | 290.82 M | ||||
| Current Liabilities | 10.12 M | ||||
Performance Metrics & Calculation Methodology
Drawdown analysis for Iovance Biotherapeutics measures how deep losses have been and how long recovery has taken historically. Comparing drawdown severity across periods reveals whether risk characteristics are stable or shifting. Iovance Biotherapeutics shows ROE of -55.5%, ROA of -27.3% (TTM) vs -45.0% (last reported).
Iovance Biotherapeutics metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Return and risk statistics are calculated from historical price series.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board